Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4%
Financings Routine −

MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 Million

MustGrow Biologics raises $3.7M to fund TerraSante ramp-up amid persistent cash burn.

By The Northwire Desk — AI Analysis Jun 17, 2026 · 19:22 MGRO · 0.445 MustGrow Biologics Corp.
Executive Summary
  • MustGrow Biologics Corp. is proceeding with the closing of its previously announced non-brokered private placement (LIFE Offering) on June 18, 2026.
  • The company has increased the offering size from the previously announced $2 million to approximately $3.7 million.
  • Approximately 7.4 million units will be issued at $0.50 per unit.
  • Each unit consists of one common share and one common share purchase warrant exercisable at $0.70 per share for 60 months.
  • Net proceeds will fund inventory production for TerraSante, working capital, and general corporate purposes.
  • Finder compensation includes up to 6.0% cash and 6.0% in non-transferable warrants.
Material Impact
  • Dilution: The issuance of ~7.4 million units increases the fully diluted share count from ~76.7 million to ~84.1 million, representing approximately 9.6% dilution.
  • Pricing: The offering price of $0.50 is above the current market price of $0.44, which is atypical for a private placement and may indicate strong insider or committed investor participation, or a strategic pricing decision to minimize immediate discount dilution.
  • Liquidity: The $3.7 million in gross proceeds (net of finder fees) provides a critical lifeline, extending the company's runway by roughly one quarter given the Q1 2026 operating cash burn of $2.28 million.
  • Strategic: Confirms management's commitment to scaling TerraSante inventory and transitioning from batch to continuous manufacturing.
MGRO · Price
Company Overview
  • MustGrow Biologics Corp. is an agricultural biotechnology company focused on developing and commercializing mustard-derived biological products.
  • Core Product: TerraSante, an organic, OMRI-listed wettable powder biofertility product designed to improve soil microbiome health, nutrient use efficiency, and crop yields.
  • Pipeline: TerraMG, a biocontrol product targeting clubroot disease in canola, with promising field trial data showing up to 95% spore reduction and yield increases.
  • Strategic Shift: The company is winding down its Canadian distribution arm, NexusBioAg, to focus exclusively on scaling TerraSante sales in the U.S. market and pursuing international partnerships, including a collaboration with Bayer for EMEA.
Read the original news release →

More from MustGrow Biologics Corp.

Jun 26, 2026 · 17:01

MustGrow Biologics Corp. Announces Results of Shareholder Meeting

Management Jun 19, 2026 · 17:01

MustGrow Biologics Raises $3.7M to Fund TerraSante Biofertility Ramp Amid Persistent Cash Burn

Financings May 28, 2026 · 17:01

MustGrow Biologics Secures Liquidity Amidst Early Revenue Growth and Manufacturing Transition

Earnings May 25, 2026 · 18:01

MustGrow Biologics Secures Capital for U.S. Expansion Amidst Revenue Growth

Financings May 25, 2026 · 07:00

Regulatory Expansion Validates Growth Strategy But Cash Burn Remains Critical Risk

Regulatory May 14, 2026 · 17:15

MustGrow Biologics Corp.

Other